Strong AYVAKIT demand and expanded market reach fuel revenue growth, while a diversified pipeline and efficient cost structure reduce reliance on a single product and support long-term earnings growth. Notably, Sanofi agreed to acquire Blueprint Medicines for $129.00 per share in cash ($9.1B total), plus potential contingent value rights payments worth up to $6 per share, bringing the total potential value to $9.5B.
Cyborg Score Rationale
Blueprint demonstrated robust Q1 2025 financial results with AYVAKIT net product revenues reaching $149.4M, representing 61% year-over-year growth. The company has achieved significant commercial traction with its first-in-class asset and maintains a diversified pipeline. However, the pending Sanofi acquisition signals transition to a larger parent company.
Top Insights
Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030
Pipeline includes elenestinib (Phase 2/3 for SM) and BLU-808 (early-stage KIT inhibitor)
As of April 2026, Blueprint Medicines' trailing twelve-month revenue is $0.56 billion USD
Blueprint Medicines exceeded the US Biotech industry which returned -13.1% over the past year
Named Competitors
Tecartus — CAR-T immunotherapy competitor in rare disease space
Venclyxto — BCL2 inhibitor in hematologic malignancies
Recent Developments
(February 2025) Updated systemic mastocytosis franchise revenue opportunity to $4 billion with AYVAKIT projected at $2 billion by 2030